In addition, future studies in nonresponders to ZIKV and PD-1 blockade combination therapy might identify mechanisms of resistance, such as loss of tumor antigens, reduction of immune infiltration surrounding the tumor, or other mechanisms of T cell anergy or exhaustion. The gene discussed is PDCD1; the disease is neoplasm.